Mauna Kea Technologies manufactures Cellvizio Lab, confocal probe based imaging system, providing cellular-level images with minimal invasiveness for longitudinal studies.
Discover
Back to filter
Show all topics (10)
Related topics
Aug 17, 2023
Register for an engaging webinar led by Naz Chaudary, Ph.D., and Research Technician, Alex Wang from the...
Optimizing Gene Expression with Bioluminescence & the piggyBac System
Aug 15, 2023
Discover how bioluminescence imaging & the piggyBac gene editing system optimize & track gene expression in mouse...
High-plex immunofluorescence imaging and traditional histology of the same tissue section
Aug 7, 2023
RareCyte Orion’ platform has been used for collecting H&E and high-plex immunofluorescence images from the same cells...
Drive key insights and discoveries with NEW Live Cell Analysis applications for eSight system
Aug 2, 2023
eSight is now powerful like never before. Learn more about new dedicated application modules for live-cell analysis: 3D...
Single cell-resolution in situ sequencing elucidates spatial dynamics of multiple sclerosis
Jul 14, 2023
MERFISH integrates spatial transcriptomics technology with high resolution spatial imaging, fluidics, image processing,...
MARS - High Efficiency Separation of CD34+ HSC from Mobilized Blood
Jul 12, 2023
MARS platform provides an easy and cost-effective protocol for CD34+ cell isolation. Single pass CD34+ HSC enrichment...
43 markers, ONE tube : Impress yourself with Cytek Aurora Spectral Cytometer
Jul 11, 2023
Using Cytek full spectrum flow cytometry, scientists at Hamad Medical Corporation, developed a 43 color panel to...
InAlyzer - The technology chosen by NASA
Jul 10, 2023
MEDIKORS's InAlyzer was finally selected as the equipment to be used for NASA's space environment biological research
Nature Article: The genomic landscape of pediatric acute lymphoblastic leukemia
Jun 29, 2023
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Here, using whole-genome, exome and...
Brain-specific biomarkers in urine as a non-invasive approach to monitor neuronal and glial damage
Jun 28, 2023
This study evaluates the quantitative measurability of glial fibrillary acidic protein (GFAP), neurofilament light...
De novo design of a biologically active amyloid
Feb 5, 2018
Most human proteins possess amyloidogenic segments, but only about 30 are associated with amyloid-associated pathologies, and it remains unclear what determines amyloid toxicity. Gallardo et al. designed vascin, a synthetic amyloid peptide, based on an amyloidogenic fragment of vascular endothelial growth factor receptor 2 (VEGFR2), a protein that is not associated to amyloidosis. Vascin recapitulates key biophysical and biochemical characteristics of natural amyloids, penetrates cells, and seeds the aggregation of VEGFR2 through direct interaction. They found that amyloid toxicity is observed only in cells that both express VEGFR2 and are dependent on VEGFR2 activity for survival. Thus, amyloid toxicity here appears to be both protein-specific and conditional—determined by VEGFR2 loss of function in a biological context in which target protein function is essential.
Brand profile
